Latest News

Date Title Topic
10 Sep 2017 ESMO 2017 Press Release: Combination Immunotherapy in Second/third Line Extends Mesothelioma Survival to 15 Months Lung and other thoracic tumours
10 Sep 2017 ESMO 2017 Press Release: Abdominal Fat a Key Cancer Driver for Postmenopausal Women
10 Sep 2017 ESMO 2017 Press Release: Study Shows ESMO Magnitude of Benefit Scale Can Be Used to Grade Orphan Drugs
10 Sep 2017 ESMO 2017 Press Release: Study Confirms Chemoradiation is Best Treatment for Locally Advanced Cervical Cancer Gynaecologic malignancies
10 Sep 2017 ESMO 2017 Press Release: Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology
09 Sep 2017 ESMO 2017: Front-Line Osimertinib Poised to Become Standard of Care in EGFR-Mutation Positive NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Durvalumab as Consolidation Therapy Prolongs PFS in Stage III NSCLC Patients Without Progression Following Platinum-based Chemoradiotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Tumour Subtype Specific Genetic Alterations Detected by Comprehensive Genomic Profiling Translational research
09 Sep 2017 ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status Gynaecologic malignancies - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Webcasts
09 Sep 2017 ESMO 2017: Daily Broadcasts
09 Sep 2017 ESMO 2017 Press Release: Durvalumab Improves Progression-free Survival in Stage III Lung Cancer Lung and other thoracic tumours
09 Sep 2017 ESMO 2017 Press Release: Patients Feel Psycho-social Impact of Chemo More Acutely Than Physical Side Effects
09 Sep 2017 ESMO 2017 Press Release: “Triggers”: a New Tool to Assess Cancer Patients’ Palliative Needs Palliative and supportive care
09 Sep 2017 ESMO 2017 Press Release: Study Identifies Factors that Limit Work Ability of Young Adult Cancer Survivors